Suda Pharmaceuticals Ltd Current ratio
Quel est le Current ratio de Suda Pharmaceuticals Ltd?
Le Current ratio de Suda Pharmaceuticals Ltd est 6.45
Quelle est la définition de Current ratio?
Le ratio actuel est un ratio de liquidité qui mesure si une entreprise dispose ou non de ressources suffisantes pour faire face à ses obligations à court terme.
The current ratio is an indication of a company's liquidity and measures the capability to meet a company's short-term obligations. It compares a firm's current assets to its current liabilities, and is expressed as current assets divided by current liabilities. The ratio is only useful when two companies are compared within industry because inter industry business operations differ substantially. To determine liquidity, the current ratio is not as helpful as the quick ratio, because it includes all those assets that may not be easily liquidated, like prepaid expenses and inventory.
Acceptable current ratios vary from industry to industry. In many cases an investor would consider a high current ratio to be better than a low current ratio, because a high current ratio indicates that the company is more likely to pay the investor back. Large current ratios are not always a good sign for investors. If the company's current ratio is too high it may indicate that the company is not efficiently using its current assets or its short-term financing facilities. If current liabilities exceed current assets the current ratio will be less than 1. A current ratio of less than 1 indicates that the company may have problems meeting its short-term obligations.
Some types of businesses can operate with a current ratio of less than one however. If inventory turns into cash much more rapidly than the accounts payable become due, then the firm's current ratio can comfortably remain less than one. Inventory is valued at the cost of acquiring it and the firm intends to sell the inventory for more than this cost. The sale will therefore generate substantially more cash than the value of inventory on the balance sheet. Low current ratios can also be justified for businesses that can collect cash from customers long before they need to pay their suppliers.
Current ratio des entreprises dans Health Care secteur sur ASX par rapport à Suda Pharmaceuticals Ltd
Que fait Suda Pharmaceuticals Ltd?
Suda Pharmaceuticals Ltd engages in the development of drug delivery technology in Australia, India, Europe and Korea. It offers ZolpiMist, an oro-mucosal spray formulation of zolpidem tartrate marketed under the brand name of Ambien or Stilnox, a non-benzodiazepine prescribed for the short-term treatment of insomnia. The company's product pipeline includes Sumatriptan, an oral spray formulation for the treatment of acute migraine; and anagrelide, a platelet lowering agent for use in thrombosis, which is used for the treatment of cancer. Suda Pharmaceuticals Ltd has license and supply agreement with Teva Pharmaceuticals International GmbH and Mitsubishi Tanabe Pharma Singapore for ZolpiMist oral spray; product development, licence, and supply agreement with Cann Pharmaceutical Australia Ltd for the development of novel oral spray of pharmaceutical-grade cannabinoid derivatives for the treatment of drug resistant epilepsy, melanoma, and motion sickness; and feasibility and option agreement with Zelira Therapeutics for the use of cannabinoids for a range of uses, including insomnia, autism, opioid reduction, anxiety, pain, and cancer. The company also has a feasibility study and option agreement with Laboratorios Ordesa, S.L. The company was formerly known as Suda Limited and changed its name to Suda Pharmaceuticals Ltd in November 2017. Suda Pharmaceuticals Ltd was incorporated in 1999 and is headquartered in Osborne Park, Australia.
Entreprises avec current ratio similaire à Suda Pharmaceuticals Ltd
- Paul Merchants a Current ratio de 6.43
- Gracell Biotechnologies a Current ratio de 6.44
- Invitae a Current ratio de 6.44
- Nuveen Massachusetts Quality Municipal Income Fund a Current ratio de 6.44
- MGP Ingredients a Current ratio de 6.44
- ReposiTrak a Current ratio de 6.44
- Suda Pharmaceuticals Ltd a Current ratio de 6.45
- Tiziana Life Sciences Ltd a Current ratio de 6.45
- Taal Distributed Information Technologies a Current ratio de 6.45
- Global Mastermind Capital a Current ratio de 6.46
- Guardant Health Cl. A a Current ratio de 6.46
- NovoCure Ltd a Current ratio de 6.46
- Integrafin Plc a Current ratio de 6.46